MedTrace Logo

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

NCT02398188 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 793

Last updated 2019-01-07

Study results available
· View outcomes & findings →

Summary

This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

Conditions

  • Central Abdominal Bulging

Interventions

DRUG

LIPO-202

DRUG

Placebo

Sponsors & Collaborators

  • Neothetics, Inc

    collaborator INDUSTRY

  • Evofem Inc.

    lead INDUSTRY

Principal Investigators

  • Maria Feldman · Neothetics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-09
Primary Completion
2015-10-29
Completion
2015-10-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02398188 on ClinicalTrials.gov